In tumors with an intact TGFβR1/2-SMAD2/3 pathway, including most SCCs, glioblastomas, and breast cancers, the activation of oncogenes synergizes with TGFβ signaling to induce EMT rather than TGI. Here, TGFB1 is linked to breast cancer.